Real-World Studies
First-line dabrafenib-trametinib linked to longer rwPFS in BRAF-mutant NSCLC cohort
Yue et alJournal of Clinical Medicine
A single-center retrospective cohort study evaluated 142 patients with unresectable stage III/IV BRAF V600-mutant non-small-cell lung cancer (NSCLC) treated between and to compare the real-world effectiveness of first-line dabrafenib plus trametinib against immunochemotherapy, chemotherapy alone, and other systemic therapies. The primary study endpoint was real-world progression-free survival (rwPFS), analyzed using propensity score matching (PSM) and multivariable Cox regression models to account for baseline confounding.
Within the cohort, 47 patients received first-line targeted therapy with dabrafenib plus trametinib and 30 received immunochemotherapy. In the unadjusted cohort, dabrafenib plus trametinib was associated with a statistically significant improvement in median rwPFS compared to immunochemotherapy (32.5 vs. 13.3 months; p = 0.004). After 1:1 propensity score matching (25 matched pairs), median rwPFS was 19.6 months for dabrafenib plus trametinib versus 12.6 months for immunochemotherapy, a difference that did not reach statistical significance (HR = 1.74, 95% CI 0.85–3.66, p = 0.12). However, multivariable adjustment demonstrated that immunochemotherapy, chemotherapy alone, and other treatment options were independently associated with significantly shorter rwPFS compared to dabrafenib plus trametinib (p < 0.05 for all comparisons). Overall survival showed no significant difference between treatment arms. Dabrafenib plus trametinib also demonstrated clinical activity in later-line settings, while evaluations regarding pyrexia and PD-L1 expression subgroups were exploratory.
Key Takeaways
- In unadjusted real-world analysis, first-line dabrafenib plus trametinib achieved a significantly longer median real-world progression-free survival compared to immunochemotherapy (32.5 vs. 13.3 months; p = 0.004) in advanced BRAF V600-mutant NSCLC.
- Following propensity score matching, median real-world progression-free survival was 19.6 months for dabrafenib plus trametinib versus 12.6 months for immunochemotherapy (HR = 1.74, 95% CI 0.85–3.66, p = 0.12), with no statistically significant difference in overall survival.
- Multivariable Cox regression demonstrated that immunochemotherapy, chemotherapy alone, and other systemic regimens were each independently associated with significantly worse real-world progression-free survival compared with first-line dabrafenib plus trametinib (all p < 0.05).
Read the original sourceJournal of Clinical Medicine
